Who Owns Creon?
Creon is owned by AbbVie Inc. (NYSE: ABBV), a publicly traded American biopharmaceutical company headquartered in North Chicago, Illinois. AbbVie inherited the brand in the 2013 spin-off from Abbott Laboratories, which had acquired it with Solvay Pharmaceuticals in 2010. Creon is the most prescribed pancreatic enzyme replacement therapy in the US, generating $1.5 billion in FY2025 sales.
Creon Timeline
Who Owns Creon?
- Parent Company: AbbVie Inc.
- Ownership Type: Wholly owned
- Acquisition Year: 2013
- Company Type: Publicly Traded
- Stock Ticker: NYSE: ABBV
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Creon | AbbVie Inc. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Creon on AmazonAdvertisement
History of Creon
- Founded: 2009
- Founders: Solvay Pharmaceuticals (developer)
- Acquired by AbbVie Inc.: 2013
Pancreatic enzyme therapy predates modern pharmaceutical regulation. Crude pancreas extracts were used for digestive failure in the early 20th century, and enteric-coated pancreatic enzyme products were sold for decades before formal FDA approval was required. Creon was built into a major brand by Solvay Pharmaceuticals in Europe, where it became the standard treatment for exocrine pancreatic insufficiency caused by cystic fibrosis, chronic pancreatitis, and pancreatic surgery.
The US market was chaotic for years because older enzyme products had never passed through the modern approval process. In 2004 the FDA effectively required pancreatic enzyme products to obtain formal approval, and in April 2009 Creon became the first PERT to win US FDA approval under that framework, giving it a regulatory head start on competitors.
Ownership moved twice in quick succession. Abbott Laboratories completed its $6.2 billion acquisition of Solvay Pharmaceuticals in February 2010. Three years later, Abbott separated into two companies, and the new AbbVie took the pharmaceuticals portfolio including Creon in January 2013.
Under AbbVie the brand has grown steadily on cystic fibrosis population gains, expanded pancreatic cancer and chronic pancreatitis diagnosis, and market leadership built through gastroenterology relationships. US sales climbed from $730 million in FY2016 to $1.512 billion in FY2025. AbbVie cites more than two million patients treated, and 2020 brought the FTC-mandated divestiture of competing Allergan PERTs to Nestlé, which left Creon facing Zenpep and Viokase under new ownership while remaining the category's clear leader.
Advertisement
About AbbVie Inc.
What does AbbVie own?
AbbVie owns a portfolio of prescription drug brands including Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta, Vraylar, Ubrelvy, Qulipta, and Elahere, plus the aesthetics products Botox Cosmetic and Juvederm acquired through the 2020 Allergan deal. All are internally held product brands rather than separate subsidiaries.
Is AbbVie publicly traded?
Yes. AbbVie trades on the New York Stock Exchange under ticker ABBV and is a component of the S&P 500. It has traded publicly since its January 2013 spin-off from Abbott Laboratories, and Abbott retains no ownership stake.
Who founded AbbVie?
AbbVie was not founded by individuals but created as a corporate spin-off from Abbott Laboratories in 2013, led at launch by CEO Richard A. Gonzalez. Its operating heritage traces to Dr. Wallace C. Abbott, who founded Abbott's predecessor drug company in Chicago in 1888.
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, Illinois, in the same suburban Chicago corridor where Abbott has long been based. Its principal offices sit at 1 North Waukegan Road.
Advertisement
How many brands does AbbVie own?
AbbVie markets roughly a dozen major product brands, led by Skyrizi, Rinvoq, Humira, Botox, Juvederm, Imbruvica, and Venclexta, plus smaller products across eye care and neuroscience. Unlike consumer conglomerates, its brands are individual prescription medicines rather than retail labels.
Who owns AbbVie?
AbbVie is owned by public shareholders, with Vanguard, BlackRock, and State Street as the largest institutional holders. Robert A. Michael serves as chairman and chief executive officer. No founding family or single shareholder controls the company.
What happened to Humira?
U.S. biosimilar competitors launched in January 2023 after AbbVie's patent settlements allowed entry. Humira worldwide revenue fell from a $21.2 billion peak in 2022 to $4.54 billion in 2025, while Skyrizi and Rinvoq grew to replace it, pushing total company revenue to a record $61.16 billion.
- Founded: 2013
- Headquarters: North Chicago, Illinois, USA
- Company Type: Publicly Traded
- Stock: NYSE: ABBV
- Revenue: $61.16 billion (FY2025)
- Employees: Approximately 55,000
Where Is Creon Made / Based?
- Headquarters: North Chicago, Illinois, USA
- Manufacturing / Operations: United States, Europe
Creon Categories & Tags
Creon Recalls & Controversies
Creon has no major product safety recall on record. Its controversies are structural and modest in scale.
Advertisement
The first is price. As an old biological product without true generic equivalence, Creon commands premium pricing that periodically draws patient complaints and media coverage about the cost of a drug made from pig pancreas. The second is historical: the FTC's 2020 order forcing rival products Zenpep and Viokase out of the Allergan deal exists precisely because regulators judged that AbbVie's acquisition of Allergan would otherwise have created a near-monopoly in PERT, a documented antitrust concern that shaped today's competitive structure.
Brands Owned by AbbVie Inc.
Healthcare PharmaceuticalsAllergan
Owned by AbbVie Inc.
Pharmaceutical and aesthetics brand owned by AbbVie since 2020, best known for Botox, Juvederm, and CoolSculpting products.
pharmaceuticalsmedical-aestheticsbotox
Healthcare PharmaceuticalsNamenda
Owned by AbbVie Inc.
Brand name for memantine, an NMDA receptor antagonist for moderate-to-severe Alzheimer's disease, owned in the US by AbbVie through the Allergan acquisition.
neurologyalzheimersdementia
Healthcare PharmaceuticalsSkyrizi
Owned by AbbVie Inc.
Skyrizi (risankizumab) is AbbVie's best-selling immunology drug, generating $17.6 billion in FY2025 sales across psoriasis, Crohn's disease, and ulcerative colitis.
prescription-drugimmunologybiologic
Advertisement
Creon Ownership: Pros & Cons
Advantages
- +Owned by a top-five pharma company with gastroenterology scale
- +First FDA-approved PERT gives deep regulatory and formulary entrenchment
- +Steady revenue growth in a market with weak generic competition
- +Specialized manufacturing creates a real barrier to entry
Considerations
- -Premium pricing invites access criticism and payer pressure
- -Biological sourcing creates supply and quality complexity
- -Category history includes an FTC-documented monopoly concern
- -Dependent on continued diagnosis-rate expansion for growth
Frequently Asked Questions About Creon
Advertisement
Sources & Further Reading
Competitors to Creon
No direct competitors found in the same category. This could be because Creonoperates in a unique market segment or we're still building our competitor database.
Advertisement
Independent Alternatives to Creon
Looking for brands with different ownership structures? These similar brands are not owned by AbbVie Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsArthrex
Owned by Arthrex Inc.
Orthopedic device brand of privately held Arthrex Inc., specializing in arthroscopic surgery products sold in more than 100 countries.
orthopedic-devicesarthroscopysports-medicine
Privately Owned
Arthrex is privately owned, unlike Creon which is under a publicly traded parent company.
Healthcare PharmaceuticalsBMG LABTECH
Owned by BMG Labtech GmbH
German life-science instrumentation company focused exclusively on microplate readers. Family-owned, founded in 1989, and based in Ortenberg, Germany.
microplate-readerslab-instrumentslife-sciences
Privately Owned
BMG LABTECH is privately owned, unlike Creon which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Creon which is under a publicly traded parent company.
Healthcare PharmaceuticalsBrainlab
Owned by Brainlab SE
Munich surgical navigation and radiotherapy software brand installed in about 4,000 hospitals worldwide.
medical-technologysurgical-navigationradiosurgery
Privately Owned
Brainlab is privately owned, unlike Creon which is under a publicly traded parent company.
Healthcare PharmaceuticalsIvoclar
Owned by Ivoclar Vivadent AG
Dental products brand of family-owned Ivoclar Vivadent AG, maker of IPS e.max ceramics and equipment sold in about 130 countries.
dental-productsdental-materialsmedical-devices
Privately Owned
Ivoclar is privately owned, unlike Creon which is under a publicly traded parent company.
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Privately Owned
Jardiance is privately owned, unlike Creon which is under a publicly traded parent company.
AbbVie Inc. Stock Information
Advertisement
Jobs at AbbVie Inc.
Latest News About Creon
Advertisement
Related Articles About Creon
View more articles
Health
The Pharmaceutical Giants Behind Common Medicines
Eli Lilly is now #1 pharma ($65.2B, Mounjaro + Zepbound). Novo Nordisk has 59.6% GLP-1 share. Merck's Keytruda is $31.7B. Pfizer faces a $20B patent cliff. Discover who makes your medicines. Explore our database.
Who Brands StaffNov 6, 2026
PharmaceuticalsEli LillyNovo Nordisk
News & Updates
Monthly IPO Roundup: October 2026 -- September's Biggest Listings
September 2026 IPOs: Shein raised $1.7B in Hong Kong's largest listing of the year and closed flat, NSE India debuted at a $46B valuation in the country's second-largest IPO, Enflame surged 179% in Shanghai, and Anthropic's $2 trillion S-1 surfaced. Full recap.
Who Brands StaffOct 1, 2026
Ipo RoundupIpoStock Market
Health
Hospital and Clinic Brand Ownership
HCA Healthcare is the largest for-profit hospital system (190 hospitals, $75.6B revenue). Tenet has 50 hospitals ($21.3B). UHS has 346 behavioral facilities. Fresenius leads dialysis. Explore our database.
Who Brands StaffNov 14, 2026
Hca HealthcareTenet HealthUhs
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandgenetic-testing
23andMe
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
Brand in Healthcare & Pharmaceuticals
dna-kitsconsumer-genomics
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care